Publications by authors named "Frank Gray"

Claim this Profile
T
Treatment and recovery from opioid use disorder: The role of pain severity in individuals with moderate to severe pain.
Allison N Tegge, Marco A R Ferreira, Peter M Garafola, Shuangshuang Xu, Michael Farrell, Frank Gray

Drug Alcohol Depend· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs.
John J Mariani, Robert L Dobbins, Amy Heath, Frank Gray, Howard Hassman

Am J Addict· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients.
Laurence M Moss, Marijke Hyke Algera, Robert Dobbins, Frank Gray, Stephanie Strafford

PLoS One· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
Ruihua Dong, Hongyun Wang, Dandan Li, Liwei Lang, Frank Gray

Drugs R D· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
XuYi Wang, Haifeng Jiang, Min Zhao, Jing Li, Frank Gray

Asia Pac Psychiatry· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study.
Joanne Ellis, Andre van Maurik, Lea Fortunato, Sophie Gisbert, Keguan Chen, Frank Gray

Br J Clin Pharmacol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of human brain PDE4 occupancy by GSK356278: A [C](R)-rolipram PET study.
Jasper van der Aart, Cristian Salinas, Rahul Dimber, Sabina Pampols-Maso, Ashley A Weekes, Frank A Gray

J Cereb Blood Flow Metab· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the safety, pharmacokinetics, pharmacodynamics, and drug-drug interaction potential of a selective Lp-PLA2 inhibitor (GSK2647544) in healthy volunteers
.
Kai Wu, Jianfeng Xu, Regan Fong, Xiaozhou Yao, Yanmei Xu, Frank Gray

Int J Clin Pharmacol Ther· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
A Richard Rutter, Alessandro Poffe, Palmina Cavallini, T Gregg Davis, Jessica Schneck, Frank A Gray

J Pharmacol Exp Ther· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers.
Jianfeng Xu, Frank Gray, Alex Henderson, Kirsty Hicks, Jiansong Yang

Clin Pharmacol Drug Dev· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET.
Khanum Ridler, Roger N Gunn, Graham E Searle, Julien Barletta, Jan Passchier, Frank A Gray

J Psychopharmacol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography.
Robert A Comley, Cristian A Salinas, Mark Slifstein, Marcella Petrone, Carmine Marzano, Frank A Gray

J Pharmacol Exp Ther· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.
Erik T te Beek, Justin L Hay, Jonathan N Bullman, Clare Burgess, Kimberly J Nahon, Frank A Gray

Br J Clin Pharmacol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contribution of SPECT measurements of D2 and 5-HT2A occupancy to the clinical development of the antipsychotic SB-773812.
Ana M Catafau, Santiago Bullich, Gianluca Nucci, Clare Burgess, Frank Gray

J Nucl Med· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Some Impressions of Certain Sessions of the National Dental Association.
B Frank Gray

Dent Regist· February 1918

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis